Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Multiple Myeloma 1Hematologic Neoplasms 1Head and Neck Neoplasms 1Carcinoma, Squamous Cell 1Breast Neoplasms 1

Interventions

pembrolizumab 4Oncolytic Virotherapy 4Cisplatin 4Cetuximab 3Radiotherapy 2Positron Emission Tomography Computed Tomography 2Nivolumab 2Magnetic Resonance Spectroscopy 2Immunohistochemistry 2Fluorouracil 2Erlotinib Hydrochloride 2Docetaxel 2technetium 99m ethylenedicysteine deoxyglucose 1ruxolitinib 1dornase alfa 1avelumab 1alovudine 1Varenicline 1VTX-2337 1Tobacco Use Cessation Devices 1Tetrahydrouridine 1TAK-981 1Ropivacaine 1Raltegravir Potassium 1Pyrimethamine 1Postmortem Imaging 1Positron-Emission Tomography 1Paclitaxel 1Oxycodone 1Neoadjuvant Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × Head and Neck Neoplasms × ruxolitinib × Clear all
NCT02593929 2017-06-08

Pharmacodynamic Effects and Predictive Biomarkers With Ruxolitinib in Operable Head and Neck Cancer

University of Pittsburgh

Phase EARLY_PHASE1 Withdrawn
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell, Head and Neck Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡